Biomerica Inc (BMRA) FinancialsBMRABiomerica Inc

Biomerica Inc (BMRA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Lab, accounting for 47.0% of total sales, equivalent to $411.00K. Other significant revenue streams include Contract Manufacturing and OTC. Understanding this composition is critical for investors evaluating how BMRA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Biomerica Inc maintains a gross margin of 8.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -97.00%, while the net margin is -97.39%. These profitability ratios, combined with a Return on Equity (ROE) of -113.80%, provide a clear picture of how effectively BMRA converts its operational activities into shareholder value.

In the context of the broader market, BMRA competes directly with industry leaders such as CLGN and NDRA. With a market capitalization of $7.41M, it holds a significant position in the sector. When comparing efficiency, BMRA's gross margin of 8.14% stands against CLGN's -422.22% and NDRA's N/A. Such benchmarking helps identify whether Biomerica Inc is trading at a premium or discount relative to its financial performance.

Biomerica's financial performance has been declining, with total revenue for Q4 2026 at $0.875 million, down from $1.5 million last year, and a net loss of $1.14 million. The gross margin has also been inconsistent, with Q4 showing a -8.11% gross margin, indicating ongoing challenges in profitability.